Teva Pharmaceuticals
TEVA
429 hedge funds and large institutions have $5.14B invested in Teva Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 125 increasing their positions, 141 reducing their positions, and 40 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
6% less call options, than puts
Call options by funds: $296M | Put options by funds: $315M
3% less funds holding
Funds holding: 440 → 429 (-11)
2.99% less ownership
Funds ownership: 50.84% → 47.85% (-3%)
7% less capital invested
Capital invested by funds: $5.55B → $5.14B (-$412M)
11% less repeat investments, than reductions
Existing positions increased: 125 | Existing positions reduced: 141
13% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 40
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MMH
Menora Mivtachim Holdings
Ramat Gan,
Israel
|
+$30.1M |
| 2 |
BMO
Beck Mack & Oliver
New York
|
+$27.3M |
| 3 |
PF
Phoenix Financial
Givatayim,
Israel
|
+$24.5M |
| 4 |
Jane Street
New York
|
+$24.4M |
| 5 |
D.E. Shaw & Co
New York
|
+$24.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$404M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
-$35.4M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$21.9M |
| 4 |
Citigroup
New York
|
-$17.5M |
| 5 |
JP Morgan Chase
New York
|
-$12M |
TEVA Hedge Fund Activity: Q3 2021 in Review
429 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q3 2021, worth a combined $5.14B — down 7.4% from $5.55B a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of TEVA and 35 opened new positions — a net loss of 5 holders — while 141 trimmed existing stakes and 125 added.
The largest buyer was Menora Mivtachim Holdings, adding an estimated $30.1M. The largest seller was Capital World Investors, cutting an estimated $404M.
- 429 institutional investors held Teva Pharmaceuticals (TEVA) as of Q3 2021, down from 440 in Q2 2021.
- Funds reported $5.14B of Teva Pharmaceuticals stock for Q3 2021, down 7.4% quarter-over-quarter.
- 35 funds opened new Teva Pharmaceuticals positions in Q3 2021 and 40 closed out, a net change of -5 holders.
- The largest Teva Pharmaceuticals buyer in Q3 2021 was Menora Mivtachim Holdings, an estimated $30.1M added.
- The largest Teva Pharmaceuticals seller in Q3 2021 was Capital World Investors, an estimated $404M sold.
Based on aggregated 13F filings for Q3 2021.